Advancing excellence in laboratory medicine for better healthcare worldwide

Education in the Use of Biomarkers in Diabetes (C-EUBD)


Name Position Country Term Time in Office
G. John Chair UK 2nd 2019 01 - 2021 12
E. English Member UK 2nd 2019 01 - 2021 12
A. Sato Member JP 1st 2019 03 - 2021 12
D. Sacks Member US 2nd 2019 01 - 2021 12
C. Weykamp Member NL 2nd 2019 01 - 2021 12
E.Lenters-Westra  Consultant  NL    

Terms of reference

  1. To maintain and further develop the network of reference laboratories for the measurement of HbA1c (through collaboration with C-TLM)
  2. To work in partnership with WHO and IDF to continue to promote the reporting of HbA1c in line with the consensus statement
  3. To work in partnership with WHO and IDF to facilitate the development and implementation of international guidelines for the use of HbA1c in the diagnosis of diabetes
  4. To work with IFCC Corporate Members to develop a consensus position on the information to be included in the Instructions for Use (IFU) as it relates to the clinical use of HbA1c methods
  5. Develop quality targets for the measurement of HbA1c and other biomarkers, and on the basis of these targets, and in conjunction with professional bodies, advise on the use of biomarkers for monitoring, diagnosis and screening of diabetes and glucose intolerance.
  6. To work with WHO and TF-POCT to recommend best practice in the use of POCT methods for the measurement of HbA1c
  7. To evaluate the clinical value of emerging biomarkers (e.g. glycated albumin) for the management of patients with diabetes and to establish whether there is a case for method harmonisation of effective new biomarkers
  8. To evaluate the emerging importance of post translational modification derived products (PTMDPs), and especially Advanced Glycation End-Products (AGEs), and work with Professional bodies on the best way of developing these for use in diabetes.
  9. To monitor the literature and advise on best practice in relation to laboratory aspects of diabetes.

List of Corresponding Members, nominated by National Societies

Name IFCC Member Society
D. Aslan Turkish Biochemical Society (TBS)
W. Cheneke Gebisa Ethiopian Medical Laboratory Association (EMLA)
E. Schleicher Deutche Gesellschaft fur Klinische Chemie und Laboratoriumsmedizin e.V. (DGKL)
A. Mosca Italian Society of Clinical Chemistry and Clinical Molecular Biology (SIBioC)
A. Coj Lithuanian Society of Laboratory Medicine
R. Kumar Dubey Nepalese Association for Clinical Chemistry (NACC)
B. Kumar Yadav Nepalese Association for Laboratory Science (NAMLS)
B. Okesina Association of Clinical Chemists Nigeria (ACCN)
R. Nanda Association of Medical Biochemists of India (AMBI)
P. Gillery Société Francaise de Biologie Clinique (SFBC)


List of Corresponding Members, nominated by Corporate Members

Name Company
S. Baraldi A. Menarini Diagnostics
R. Molinaro Siemens Healthcare

Committee Chair's contact

Prof. Garry JOHN
Consultant Clinical Biochemist
and Head of Clinical Biochemistry
Norfolk and Norwich University Hospital
Tel: +44 (0) 1603 286 933

Website developed by Insoft Digital